Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2012

01-01-2012 | Original Article

Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours

Authors: Nils F. Schreiter, Winfried Brenner, Munenobu Nogami, Ralph Buchert, Alexander Huppertz, Ulrich-Frank Pape, Vikas Prasad, Bernd Hamm, Martin H. Maurer

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2012

Login to get access

Abstract

Purpose

Although somatostatin receptor positron emission tomography (PET)/CT is gaining increasing popularity and has shown its diagnostic superiority in several studies, 111In-diethylenetriaminepentaacetic acid (DTPA)-octreotide is still the current standard for diagnosis of neuroendocrine tumours (NET). The aim of this study was to compare the costs for the two diagnostic tests and the respective consequential costs.

Methods

From January 2009 to July 2009, 51 consecutive patients with enteropancreatic NET who underwent contrast-enhanced 68Ga-DOTATOC PET/CT (n = 29) or 111In-DTPA-octreotide (mean 3 whole-body scans plus 1.6 low-dose single photon emission computed tomography/CT; n = 22) were included. For cost analysis, direct costs (equipment) and variable costs (material, labour) per examination were calculated. Additionally required CT and/or MRI examinations within the staging process were assessed as consequential costs. An additional deterministic sensitivity analysis was performed.

Results

A 68Ga-DOTATOC PET/CT examination yielded total costs (equipment, personnel and material costs) of 548 €. On the other hand, an 111In-DTPA-octreotide examination resulted in 827 € total costs. Costs for equipment and material had a share of 460 €/720 € for 68Ga-DOTATOC/111In-DTPA-octreotide and labour costs of 89 €/106 €. With 68Ga-DOTATOC additional MRI had to be performed in 7% of the patients resulting in a mean of 20 € for supplementary imaging per patient; 82% of patients with 111In-DTPA-octreotide needed additional MRI and/or CT resulting in mean additional costs of 161 € per patient.

Conclusion

68Ga-DOTATOC PET/CT was considerably cheaper than 111In-DTPA-octreotide with respect to both material and personnel costs. Furthermore, by using 68Ga-DOTATOC PET/CT considerably fewer additional examinations were needed reducing the consequential costs significantly.
Literature
1.
go back to reference Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934–59.PubMedCrossRef Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934–59.PubMedCrossRef
2.
go back to reference Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009;90(2):162–6.PubMedCrossRef Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009;90(2):162–6.PubMedCrossRef
3.
go back to reference Rambaldi PF, Cuccurullo V, Briganti V, Mansi L. The present and future role of (111)In pentetreotide in the PET era. Q J Nucl Med Mol Imaging 2005;49(3):225–35.PubMed Rambaldi PF, Cuccurullo V, Briganti V, Mansi L. The present and future role of (111)In pentetreotide in the PET era. Q J Nucl Med Mol Imaging 2005;49(3):225–35.PubMed
4.
go back to reference Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716–31.PubMedCrossRef Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716–31.PubMedCrossRef
5.
go back to reference Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37(7):1441–8.PubMedCrossRef Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37(7):1441–8.PubMedCrossRef
6.
go back to reference Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5(1):42–8.PubMedCrossRef Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5(1):42–8.PubMedCrossRef
7.
go back to reference Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(10):1617–26.PubMedCrossRef Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(10):1617–26.PubMedCrossRef
8.
go back to reference Hartmann H, Zöphel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, et al. Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin 2009;48(5):201–7.PubMed Hartmann H, Zöphel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, et al. Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin 2009;48(5):201–7.PubMed
9.
go back to reference Gocke P, Debatin JF, Dürselen LF. Process management and controlling in diagnostic radiology in the hospital. Radiologe 2002;42(5):332–43.PubMedCrossRef Gocke P, Debatin JF, Dürselen LF. Process management and controlling in diagnostic radiology in the hospital. Radiologe 2002;42(5):332–43.PubMedCrossRef
10.
go back to reference Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 2001;42(7):1134–8.PubMed Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 2001;42(7):1134–8.PubMed
11.
go back to reference Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48(10):1741–8.PubMedCrossRef Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48(10):1741–8.PubMedCrossRef
12.
go back to reference Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26(18):3063–72.PubMedCrossRef Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26(18):3063–72.PubMedCrossRef
13.
go back to reference Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 2010;17(3):49–64.PubMedCrossRef Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 2010;17(3):49–64.PubMedCrossRef
14.
go back to reference Janson ET, Sørbye H, Welin S, Federspiel B, Grønbaek H, Hellman P, et al. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 2010;49(6):740–56.PubMedCrossRef Janson ET, Sørbye H, Welin S, Federspiel B, Grønbaek H, Hellman P, et al. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 2010;49(6):740–56.PubMedCrossRef
15.
go back to reference Arnold R, Chen YJ, Costa F, Falconi M, Gross D, Grossman AB, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009;90(2):227–33.PubMedCrossRef Arnold R, Chen YJ, Costa F, Falconi M, Gross D, Grossman AB, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009;90(2):227–33.PubMedCrossRef
16.
go back to reference Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90(2):167–83.PubMedCrossRef Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90(2):167–83.PubMedCrossRef
17.
go back to reference Plathow C, Walz M, Lichy MP, Aschoff P, Pfannenberg C, Bock H, et al. Cost considerations for whole-body MRI and PET/CT as part of oncologic staging. Radiologe 2008;48(4):384–96.PubMedCrossRef Plathow C, Walz M, Lichy MP, Aschoff P, Pfannenberg C, Bock H, et al. Cost considerations for whole-body MRI and PET/CT as part of oncologic staging. Radiologe 2008;48(4):384–96.PubMedCrossRef
18.
go back to reference Schmidt GP, Haug AR, Schoenberg SO, Reiser MF. Whole-body MRI and PET-CT in the management of cancer patients. Eur Radiol 2006;16(6):1216–25.PubMedCrossRef Schmidt GP, Haug AR, Schoenberg SO, Reiser MF. Whole-body MRI and PET-CT in the management of cancer patients. Eur Radiol 2006;16(6):1216–25.PubMedCrossRef
19.
go back to reference Baum RP, Prasad V, Hörsch D. Molekulare Bildgebung neuroendokriner Tumoren mit 68Ga-markierten Peptiden (Somatostatinrezeptor-PET/CT). Nuklearmediziner 2009;32:115–30.CrossRef Baum RP, Prasad V, Hörsch D. Molekulare Bildgebung neuroendokriner Tumoren mit 68Ga-markierten Peptiden (Somatostatinrezeptor-PET/CT). Nuklearmediziner 2009;32:115–30.CrossRef
20.
go back to reference Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1(8632):242–4.PubMedCrossRef Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1(8632):242–4.PubMedCrossRef
21.
go back to reference Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33(5):652–8.PubMed Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33(5):652–8.PubMed
22.
go back to reference Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, et al. Gallium-67/gallium-68-[DFO]-octreotide–a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35(2):317–25.PubMed Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, et al. Gallium-67/gallium-68-[DFO]-octreotide–a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35(2):317–25.PubMed
23.
go back to reference de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24(4):368–71.PubMedCrossRef de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24(4):368–71.PubMedCrossRef
24.
go back to reference Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351(9100):417–8.PubMedCrossRef Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351(9100):417–8.PubMedCrossRef
25.
go back to reference Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34(7):982–93.PubMedCrossRef Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34(7):982–93.PubMedCrossRef
26.
go back to reference Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, et al. Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 2010;91(1):101–9.PubMedCrossRef Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, et al. Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 2010;91(1):101–9.PubMedCrossRef
27.
go back to reference Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508–18.PubMedCrossRef Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508–18.PubMedCrossRef
28.
go back to reference Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. (68)Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (111)In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 2011;13(3):583–93.PubMedCrossRef Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. (68)Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (111)In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 2011;13(3):583–93.PubMedCrossRef
Metadata
Title
Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours
Authors
Nils F. Schreiter
Winfried Brenner
Munenobu Nogami
Ralph Buchert
Alexander Huppertz
Ulrich-Frank Pape
Vikas Prasad
Bernd Hamm
Martin H. Maurer
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-1935-5

Other articles of this Issue 1/2012

European Journal of Nuclear Medicine and Molecular Imaging 1/2012 Go to the issue